|Treatment Intensification Rates, Baseline Risk Factor Levels, Declines and Adjusted Differences During Follow-up - Study vs. Control Centers, Eligible Patients, by Priority Level|
|Study (n = 4 sites)||Control (n = 4 sites)|
|Priority||Number Eligible Patients||Intensified within 3 months||Baseline Mean Risk Factor Level†||
|Number Eligible Patients||Intensified within 3 months||Baseline Mean Risk Factor Level†||
Study-Control Risk Factor Differences
|1: SBP ≥ 140||3,080||34.1€||153.2||13.6||2,905||30.6€||153.0||13.4||0.73|
|2: LDL-c ≥ 130||2,431||28.0€||153.1||24.9||1,789||22.7€||153.9||23.8||-2.63|
|3: A1c ≥ 9%||1,318||29.5||10.2||1.0||1,059||28.8||10.2||1.2||-0.02|
|5: LDL-c 100-129||4,876||20.5||111.4||10.1||3,526||19.1||111.3||8.9||-0.83|
|6. A1c 7-8.9%||3,750||26.3||7.5||0||3,007||26.9||7.5||0||0.03|
† Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.
‡ Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first 3 months follow-up was used. No values were available during follow-up for 3%, 10%, and 14% of blood pressure, A1c, and LDL-c tests, respectively.
¶ From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number of medications for the risk factor at baseline, and days of follow-up at time of each measurement. Negative value indicates that the adjusted difference favored the study group group during follow-up.
€ p < 0.001 for study vs. control comparison.
£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.
Selby et al. BMC Health Services Research 2012 12:183 doi:10.1186/1472-6963-12-183